Neil P. Shah, MD, PhD, received his BS from the University of California, Berkeley, and his MD and PhD degrees from the UCLA School of Medicine. He remained at UCLA for his Internship and Residency training in Internal Medicine, as well as his fellowship training in Hematology and Oncology. He performed postdoctoral research in the laboratory of Charles Sawyers, where his translational studies led directly to the clinical investigation and FDA approval of dasatinib, a transformative therapy for patients with chronic myeloid leukemia (CML).

He joined the UCSF faculty in 2006 and is the Edward S. Ageno Distinguished Professor in Hematology/Oncology at the University of California, San Francisco School of Medicine. He also serves as Director of the UCSF Molecular Medicine Residency Program. He is an internationally known as an expert in targeted therapy for CML and is Chair of the National Comprehensive Cancer Network Chronic Myeloid Leukemia Guidelines Panel. His laboratory continues to conduct molecular studies of human leukemias and attempts to translate expanding knowledge of the genetics of these diseases toward the development of more active and better tolerated targeted therapeutics.